News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Month Year

Dec 14, 2021

Astellas and MBC BioLabs Announce Future Innovator Prize Winners - Helping Biotech Start-ups Accelerate Early Research Efforts

- Vcreate and Weatherwax Biotechnologies win a year of access to life-science incubator in San Francisco, CA and to Astellas expertise to further their research -
Dec 1, 2021

Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle

- Dyno receives $18 million upfront and is eligible for milestone and royalty payments potentially exceeding $1.6 billion -
Dec 1, 2021

Astellas to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia - from Diagnosis to Relapse - at 2021 American Society of Hematology Annual Meeting

- Four AML oral presentations are among highest number of Astellas-sponsored ASH abstracts to date
Nov 17, 2021

The Astellas Global Health Foundation provides $1.85 million in funding to five organizations focused on improving health and COVID-19 recovery efforts for more than four million people in low-income communities

New grants will support needed education, training and community resilience in five countries
- Photos 1
Nov 3, 2021

Astellas and LabCentral Announce Future Innovator Prize Winners - Helping Emerging Biotechs Accelerate Growth of Innovative Science

- Thymmune Therapeutics and M13 Therapeutics win a year of access to life-science incubator in Cambridge, MA and access to Astellas expertise to further their research -
Oct 12, 2021

Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Sep 28, 2021

Astellas Recognized Consistently Among Top Companies for Working Parents

Astellas ranked again in Seramount's 100 Best Companies and Best Companies for Dads lists.
Sep 27, 2021

Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer

- Enfortumab vedotin is the first and only antibody-drug conjugate (ADC) approved in Japan for patients with advanced urothelial cancer -
Sep 22, 2021

Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ Trial in Oral Session at The North American Menopause Society 2021 Annual Meeting

Astellas' investigational non-hormonal treatment demonstrates reduction in frequency and severity of moderate to severe vasomotor symptoms (VMS) associated with menopause
Sep 21, 2021

Astellas and MBC BioLabs Announce Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators

Show per page

Statements

Careers

Stay Connected

Get only the email alerts you want.

Media Contacts

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

Download Fact Sheet

Sustainability

Investors

Explore U.S. Products

News Releases

You are now leaving XTANDI.com

You are now leaving newsroom.astellas.com.